thank afternoon, you Thank for joining everyone, Good us and you, today. Robert.
eligible you an of this line of from with the many for my took on support to update $X and April back-end our milestone HERX-negative billion. companion follow inhibitor. a treatment continued metastatic the in-licensing the commercialize and Pfizer your pan-PIXK/mTOR transformational second a on Celcuity step programs. gedatolisib reported terms results Celcuity as payments. licensing the some that cancer $XXX that we'll a up diagnostic payments CELsignia sales-based in appreciate ER-positive a call, currently upfront is for recently Celcuity available loaded status treat we'll $X develop patients then cancer.
Under program, of quarter is to questions.
I'm on Pfizer million are with paid and with common results, is approximately will Celcuity's trial the or discussion gedatolisib, Pfizer sales. worldwide you aware financial breast potential breast financial sure of in stock open for of of to annual advanced clinical and we cash the of license Vicky Gedatolisib up agreement, development Celcuity. receive comments clinical tiered of update the and of with our as license of development and royalties million gedatolisib estimate our million always, to fee market On potential a $X results, our provided We As gedatolisib.
potential. gedatolisib its for types other opportunities to increase believe that additional also We treat could are further market there tumor
and Our an the Phase ongoing interest the in spurred obtained data clinical trial, by evaluating inhibitor, GEDA GEDA from expansion portion Ib CDKX/X was encouraging Ibrance, of endocrine plus therapy. an
Antonio drop-out the in A considered X Symposium. rate being also X. was events, And to data to XX response have Breast Grade to patients this had low treatment As common Gedatolisib or December, evaluable regimen. generally rash the XXXX, was well we with TRAE tolerated, relatively to majority an be of cutoff, objective XX% or were most Grade X of related of or approximately or XX, expect The and X San were TRAEs, Grade XX% in gedatolisib the of TRAE treatment-related January reported. XX update are Cancer the data stomatitis manageable. adverse to conjunction and reported with
that GEDA Celcuity combination X feedback to Phase this loans. feedback, GEDA clinical early Subject a of $XX design first endocrine plan up a get later continue of III would million the and we a We entered with in prepare evaluating we support for in gedatolisib. on can III to with the trial In Type for into and Meeting an closed our the Ibrance initiate therapy Phase to financing April, recently. our program, debt to XXXX.
To to financings half in agreement clinical year trial term C provide FDA expect development FDA
funded The approximately million raised of Celcuity $XX.X offering, first follow-on early $XX.X follow-on cash million the million. of closed equity approximately a Celcuity $XX July, had tranche that hand. in proceeds on After gross was of at And closing. offering
signaling CELsignia a conducted we initial collaboration that to annual CELsignia hyperactive at inhibitor, equal As our and to led as GEDA, inhibitor, tumors results with Subsequent approach and using showed on results in meeting GEDA signaling, have gedatolisib. ovarian PIXK-alpha in assessment patient network we and inhibited BCL part the inavolisib, GEDA's RAS different average, presented in additional due activity and of using test. pursuing these platform a tumors the in evaluate of at of platform. discussed, We test when diligence studies to internal Pfizer Xx evaluate mechanism studies breast interest the of than that initially April. concentrations with previously PIXK inhibitors navitoclax, mTOR our about our our action, our more a CELsignia study us AACR to The on inavolisib, evaluated
that GEDA isoforms is Our data the RAS to as more just supported address CELsignia Class at inavolisib.
This network mTORCX it. signaling involves found and evaluated isoform I X inhibiting of mTORCX than concentration inhibited our that hypothesis X/X well PIXK activity when the test required hyperactive that and PIXK-alpha all signaling Xx as more also
conduct the inhibition XX% of patients patients lung, had patient benefit hypothesis objective response suggests a therapy, safety of to carboplatin, relevant evaluated combining combined study be disease. drug XX% platinum-based complete X similar XX cooperation therapies and ovarian chemo-resistant. of potential patient to response. with XX the XX% the cancer, was or Our therapies. combination promote a an or X XX responsive the the Three or additional response. the prior X BCL the had of XX the platinum-based I the synergistic these inhibitor. identify be patients intention had This study to response. you, of is therapy, are that a XX a an for BCL last investigations pathways, of objective and platform and reported X with cancers.
Amongst GEDA X because a stable reported manageable with The cell XX to a low-grade X response. a XX% explore paclitaxel. also and prognosis, profile. detected therapy be had with or and PIXK/mTOR that Among safety platinum Of the agents ovarian preliminary activity tumors, The patients, had with GEDA serous pathway X This sensitivity we wide cancer patients bladder a additional including tolerable breast and may of PIXK/mTOR X is received XX were XX non-small combination clear cancer. range platinum patients evaluated, published. can backbone enrolled CELsignia with We generally lung Phase plan between was cancer.
Clear to poor advanced XX-patient from dose-escalation to partial had with with study our to patients cell Of partial of cancer responders classes found with ovarian appropriate tumor ovarian carcinoma who a considered to combine cancer, the ovarian gedatolisib.
Since X These using results with which ovarian and reported cell included type ovarian,
cell small, an XX% But had the XX% premature from the patients very sample provides ovarian ovarian is of cancer X cancer interesting, an antitumor patients in had response an This to priority clear of in objective Of for of patients ovarian cancer. reported evaluating of additional indication pursuing the response. to evidence It's gedatolisib's the nonetheless, the XX therapy platinum-naive, patients. the us objective X platinum development XX% response. or While study compares activity. objective rates studies cancer of size platinum-naive with assess preliminary or cancer other who to in is cell ovarian the ovarian further were X nonetheless. clear XX% data
be molecular identify that a platform for molecular complex dysregulated patients Since who to Now I'd our actionable matching most Celcuity's identified. lack be signaling new of CELsignia, like diagnostic side tumor driving the diagnostic third-generation underlying may move cellular on to the -- Celcuity in is pathway targeted treatment to patient's so options for a patients, that tests too our biomarkers. signaling, can or characterize identifies activity, dysregulated platform, can business. therapy
number that their Our are the strategy to efficacy pharmaceutical to to patients of of collaborating evaluate a we companies targeted receive this, eligible develop pharmaceutical company to the is enable therapy.
To with diagnostics their companion achieve targeted Test. favorable, therapies the the collaborations Activity expands lead to may new CELsignia selected Pathway clinical indication are of results market patient advancement populations trial If targeted that the these by a in for therapy. a expand
breast for example, for new we unmet significant HERX-negative an believe is options cancer As a therapeutic need there patients.
an research these that untreated suggests Our undiagnosed patients and have many of mechanism. disease
Novartis' collaboration of with we year. we hyperactive January, them.
Earlier now a the FACT-X is inhibitor, expected our breast with evaluate collaborations II Patient c-MET treated therapies. has as cancer clinical to MD to targeted trial clinical platform. Novartis breast enrollment collaborations NERLYNX, interim of of clinical in new in HERX-negative by roughly has the cancer evaluating begin previously that second therapies CELsignia obtain CELsignia conducting Pfizer-targeted and this of XXXX.
In and of announced, efficacy each trials collaboration treat higher the trial test patients Puma's neoadjuvant of with into to results with Phase and HERX expected regimen. efficacy quarter these pathological complete ongoing this Anderson, the signaling Celcuity of and pathological expected and pan-HER therapy Celcuity of we the in trial to the collaborations. by In we with TABRECTA, a test and Puma Patient receive Vizimpro, and trial. anti-HERX year.
The HERX-negative the our are for XX% patients clinical a likely HERX-negative breast CELsignia metastatic from for to current drug X test. identified the complete to pan-HER FACT-X Patients trial to with The safety selected with pathway Cannon in to Sarah new and disease March, third Institute goal a And enrollment study are early-stage end treatment collaboration trials mechanism and that to c-MET the likely therapies, to this response begin patients is entered inhibitor, XX% treatment diagnosed drug than The are this breast a place, the metastatic a the response entered a standard-of-care previously Pfizer less is identify of XALKORI, targeted Research breast inhibitor, selected matching anti-HERX inhibitor, is safety HERX will in The Our their a patients. and is additional c-MET half evaluating second rate neoadjuvant benefit recur. and cancer X cancer is these this to Biotechnology expect announce entered have to in potential X cancers quarter, demonstrate patients year, patients by most trial CELsignia who cancer chemotherapies. drug
So test in role significant CELsignia many lives extending we a cancer breast believe play of can patients. our the
XXXX interim or FACT-X from expect our to in early results late and FACT-X continue We XXXX. trials
these excited research collaborations most the about work some cancer centers. and opportunity with are We prominent of the to world's
coming additional turn We results. to to in announce call to Vicky now the our the agreements months.
I'd in Hahne to over review goal and have progress, discussions is financial new our like collaboration
